Multi-drug resistant gram-negatives

MDR Gram-Negatives - The Usual Suspects

• Key Pathogens (SPACE-E):

  • Serratia
  • Pseudomonas aeruginosa
  • Acinetobacter baumannii
  • Citrobacter
  • Enterobacter spp.
  • Escherichia coli (not traditionally SPACE, but a major MDR threat)
  • Klebsiella pneumoniae

• Primary Resistance Mechanisms:

  • Enzymatic Degradation: Extended-spectrum β-lactamases (ESBLs) & Carbapenemases (KPC, NDM, OXA).
  • Efflux Pumps: Multi-drug efflux systems (e.g., MexAB-OprM in Pseudomonas).
  • Target Modification/Protection: e.g., Porin loss to block antibiotic entry.

⭐ Carbapenem-resistant Enterobacteriaceae (CRE) infections can have mortality rates approaching 50%. Resistance is often carried on mobile genetic elements (plasmids), facilitating rapid spread.

Resistance Mechanisms - Their Bag of Tricks

• Enzymatic Degradation: Bacteria produce enzymes that destroy the antibiotic.
  • β-Lactamases: The most common mechanism against β-lactam antibiotics.
    • ESBLs (Extended-Spectrum β-Lactamases): Inactivate most penicillins & cephalosporins.
    • AmpC β-Lactamases: Chromosomally inducible or plasmid-mediated; resist cephamycins.
    • Carbapenemases: Degrade carbapenems, the last-resort antibiotics (e.g., KPC, NDM-1, OXA).
• Target Site Modification: Altering the drug's binding site reduces its efficacy.
  • Examples: Changes in Penicillin-Binding Proteins (PBPs) → Methicillin resistance (MRSA).
• Reduced Permeability & Active Efflux:
  • Porin Channel Loss: Decreased entry of antibiotics into the bacterial cell.
  • Efflux Pumps: Actively pump the antibiotic out of the cell (e.g., TetA for tetracycline).

⭐ High-Yield: Carbapenemase genes are often located on plasmids, facilitating rapid horizontal transfer between different bacterial species and leading to widespread resistance.

📌 Mnemonic: Remember the core mechanisms with "E.A.T."

• Enzymatic degradation
• Altered target site
• Transport (reduced permeability/efflux)

Treatment Strategies - The Big Guns

• Core Principle: Use newer agents based on resistance mechanism, often requiring combination therapy.

• Last-Resort Agents (High Toxicity):

  • Polymyxins (Colistin, Polymyxin B): High rates of nephrotoxicity and neurotoxicity. Used when other options are exhausted.
  • Tigecycline: Broad spectrum, but bacteriostatic. ⚠️ Increased mortality (black box warning); poor choice for bacteremia.

• Other Key Agents:

  • Cefiderocol: Siderophore cephalosporin; active against many CRE, including MBLs.
  • Eravacycline, Omadacycline: Newer tetracyclines with activity against some resistant strains.

⭐ High-Yield: For severe CRE infections, especially those caused by metallo-β-lactamases (MBLs), combination therapy (e.g., ceftazidime-avibactam plus aztreonam) is often required as single agents may be ineffective.

High‑Yield Points - ⚡ Biggest Takeaways

• MDR gram-negatives are a major threat in healthcare settings, causing high-mortality infections like HAP/VAP and sepsis.
• Key pathogens: CRE (Carbapenem-resistant Enterobacteriaceae), MDR Pseudomonas, and Acinetobacter baumannii.
• Primary resistance mechanism: beta-lactamase enzymes (e.g., ESBLs, KPCs) that destroy most beta-lactam antibiotics.
• Resistance genes are typically on plasmids, allowing for rapid horizontal gene transfer between different bacterial species.
• Treatment often requires last-resort drugs like colistin, tigecycline, or newer beta-lactamase inhibitor combinations.